Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products

Ohseok Kwon, Jeewon Joung, Younjoo Park, Chan Wha Kim, Seung Hwa Hong

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Based on experience in clinical trial approvals and marketing authorizations for biosimilar products in Korea, we suggest principles for the analytical comparability assessment of biosimilar products with respect to regulatory considerations. The composition and manufacturing processes of biosimilar products can differ from those of the reference product depending on the information available for the reference product and the time of product development; however, the analytical characteristics of biosimilar products should be highly similar to those of the reference product. Although manufacturing an identical product in terms of the quality profile is nearly impossible due to the high molecular weight and complex structure of biological products, the developer of the biosimilar product should attempt to establish a quality level as similar to that of the reference product as possible. When comparing the similarity of quality attributes, the criticality of the quality attributes and the characteristics of orthogonal quality attributes need to be considered carefully. Based on the results from the analytical comparability assessment, the comparability results of non-clinical and clinical studies should be evaluated before claiming biosimilarity to the reference product. In this review, we focus on quality attribute evaluation based on our regulatory experience.

Original languageEnglish
JournalBiologicals
DOIs
Publication statusAccepted/In press - 2016 Dec 28

Fingerprint

Biosimilar Pharmaceuticals
Product development
Marketing
Molecular weight
Chemical analysis
Korea
Biological Products
Molecular Weight
Clinical Trials

Keywords

  • Analytical comparability
  • Biosimilar product
  • Biosimilarity
  • Criticality
  • Monoclonal antibody
  • Quality attribute

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology
  • Immunology and Microbiology(all)
  • Pharmacology

Cite this

Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products. / Kwon, Ohseok; Joung, Jeewon; Park, Younjoo; Kim, Chan Wha; Hong, Seung Hwa.

In: Biologicals, 28.12.2016.

Research output: Contribution to journalArticle

@article{51d05d9154224a5a833b78f274350cc2,
title = "Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products",
abstract = "Based on experience in clinical trial approvals and marketing authorizations for biosimilar products in Korea, we suggest principles for the analytical comparability assessment of biosimilar products with respect to regulatory considerations. The composition and manufacturing processes of biosimilar products can differ from those of the reference product depending on the information available for the reference product and the time of product development; however, the analytical characteristics of biosimilar products should be highly similar to those of the reference product. Although manufacturing an identical product in terms of the quality profile is nearly impossible due to the high molecular weight and complex structure of biological products, the developer of the biosimilar product should attempt to establish a quality level as similar to that of the reference product as possible. When comparing the similarity of quality attributes, the criticality of the quality attributes and the characteristics of orthogonal quality attributes need to be considered carefully. Based on the results from the analytical comparability assessment, the comparability results of non-clinical and clinical studies should be evaluated before claiming biosimilarity to the reference product. In this review, we focus on quality attribute evaluation based on our regulatory experience.",
keywords = "Analytical comparability, Biosimilar product, Biosimilarity, Criticality, Monoclonal antibody, Quality attribute",
author = "Ohseok Kwon and Jeewon Joung and Younjoo Park and Kim, {Chan Wha} and Hong, {Seung Hwa}",
year = "2016",
month = "12",
day = "28",
doi = "10.1016/j.biologicals.2017.04.005",
language = "English",
journal = "Biologicals",
issn = "1045-1056",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - Considerations of critical quality attributes in the analytical comparability assessment of biosimilar products

AU - Kwon, Ohseok

AU - Joung, Jeewon

AU - Park, Younjoo

AU - Kim, Chan Wha

AU - Hong, Seung Hwa

PY - 2016/12/28

Y1 - 2016/12/28

N2 - Based on experience in clinical trial approvals and marketing authorizations for biosimilar products in Korea, we suggest principles for the analytical comparability assessment of biosimilar products with respect to regulatory considerations. The composition and manufacturing processes of biosimilar products can differ from those of the reference product depending on the information available for the reference product and the time of product development; however, the analytical characteristics of biosimilar products should be highly similar to those of the reference product. Although manufacturing an identical product in terms of the quality profile is nearly impossible due to the high molecular weight and complex structure of biological products, the developer of the biosimilar product should attempt to establish a quality level as similar to that of the reference product as possible. When comparing the similarity of quality attributes, the criticality of the quality attributes and the characteristics of orthogonal quality attributes need to be considered carefully. Based on the results from the analytical comparability assessment, the comparability results of non-clinical and clinical studies should be evaluated before claiming biosimilarity to the reference product. In this review, we focus on quality attribute evaluation based on our regulatory experience.

AB - Based on experience in clinical trial approvals and marketing authorizations for biosimilar products in Korea, we suggest principles for the analytical comparability assessment of biosimilar products with respect to regulatory considerations. The composition and manufacturing processes of biosimilar products can differ from those of the reference product depending on the information available for the reference product and the time of product development; however, the analytical characteristics of biosimilar products should be highly similar to those of the reference product. Although manufacturing an identical product in terms of the quality profile is nearly impossible due to the high molecular weight and complex structure of biological products, the developer of the biosimilar product should attempt to establish a quality level as similar to that of the reference product as possible. When comparing the similarity of quality attributes, the criticality of the quality attributes and the characteristics of orthogonal quality attributes need to be considered carefully. Based on the results from the analytical comparability assessment, the comparability results of non-clinical and clinical studies should be evaluated before claiming biosimilarity to the reference product. In this review, we focus on quality attribute evaluation based on our regulatory experience.

KW - Analytical comparability

KW - Biosimilar product

KW - Biosimilarity

KW - Criticality

KW - Monoclonal antibody

KW - Quality attribute

UR - http://www.scopus.com/inward/record.url?scp=85019015284&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019015284&partnerID=8YFLogxK

U2 - 10.1016/j.biologicals.2017.04.005

DO - 10.1016/j.biologicals.2017.04.005

M3 - Article

C2 - 28495312

AN - SCOPUS:85019015284

JO - Biologicals

JF - Biologicals

SN - 1045-1056

ER -